Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis EUR-Denominated Long-Term Debt Converted to USD by Year
EUR-Denominated Long-Term Debt Converted to USD ($M)
Novartis EUR-Denominated Long-Term Debt Converted to USD: $5,911M in FY2025, up 12.8% from a year earlier.
Latest, FY2025
5,911
Period ended Dec 31, 2025
Change on a year earlier
+12.8%
5,238 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F Note 19.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | EUR-Denominated Long-Term Debt Converted to USD ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,911 | +12.8% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 5,238 | -5.8% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 5,563 | -25.6% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2022 | Dec 31, 2022 | 7,478 | -5.7% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2021 | Dec 31, 2021 | 7,930 | -27.2% | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
| FY2020 | Dec 31, 2020 | 10,888 | +38.5% | Novartis Form 20-F (0001370368-22-000010) ↗ |
| FY2019 | Dec 31, 2019 | 7,861 | -2.1% | Novartis Form 20-F (0001370368-21-000006) ↗ |
| FY2018 | Dec 31, 2018 | 8,028 | +41.0% | Novartis Form 20-F (0001370368-20-000003) ↗ |
| FY2017 | Dec 31, 2017 | 5,695 | – | Novartis Form 20-F (0001370368-19-000002) ↗ |
Cite this data
StockData. (2026). Novartis EUR-Denominated Long-Term Debt Converted to USD ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/debt-by-currency-eur
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.